Journal Information
Vol. 7. Issue 6.
Pages 627-662 (November - December 2001)
Share
Share
Download PDF
More article options
Vol. 7. Issue 6.
Pages 627-662 (November - December 2001)
DOI: 10.1016/S0873-2159(15)31243-5
Open Access
INTRODUÇÃO
Visits
...
Article information
Full text is only aviable in PDF
BIBLIOGRAFIA
[1.]
National Heart, Lung, And Blood Institute.
Morbidity & mortality: chartbook on cardiovascular, lung, and blood diseases.
[2.]
C.J.L. Murray, A.D. Lopez.
Evidence-based health policy - lessons from the global burden of disease study.
Science, 274 (1996), pp. 740-743
[4.]
A.T. Hill, D. Bayley, R.A. Stockley.
The interrelationship of sputum inflammatory markers in patients with chronic bronchitis.
Am J Respir Crit Care Med, 160 (1999), pp. 893-898
[5.]
V.M. Keatings, P.D. Collins, D.M. Scott, P.J. Barnes.
Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma.
Am J Respir Crit Care Med, 153 (1996), pp. 530-534
[6.]
A. Pesci, B. Balbi, M. Majori, G. Cacciani, S. Bertacco, P. Alciato, et al.
Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease.
Eur Respir J, 12 (1998), pp. 380-386
[7.]
C. Yamamoto, T. Yoneda, M. Yoshikawa, A. Fu, T. Tokuyama, K. Tsukaguchi.
Airway inflammation in COPD assessed by sputum levels of interleukin-8.
Chest, 112 (1997), pp. 505-510
[8.]
R. Mueller, P. Chanez, A.M. Campbell, J. Bousquet, C. Heusser, G.R. Bullock.
Different cytokine patterns in bronchial biopsies in asthma and chronic bronchitis.
Respir Med, 90 (1996), pp. 79-85
[9.]
J.B. Mullen, J.L. Wright, B.R. Wiggs, P.D. Pare, J.C. Hogg.
Reassessment of inflammation of airways in chronic bronchitis.
BMJ, 291 (1985), pp. 1235-1239
[10.]
M. Cosio, H. Ghezzo, J.C. Hogg, R. Corbin, M. Loveland, J. Dosman, et al.
The relations between structural changes in small airways and pulmonary-function tests.
N Engl J Med, 298 (1978), pp. 1277-1281
[11.]
D.E. Niewoehner, J. Kleinerman, D.B. Rice.
Pathologic changes in the peripheral airways of young cigarette smokers.
N Engl J Med, 291 (1974), pp. 755-758
[12.]
J.L. Wright, L.M. Lawson, P.D. Pare, B.J. Wiggs, S. Kennedy, J.C. Hogg.
Morphology of peripheral airways in current smokers and ex-smokers.
Am Rev Respir Dis, 127 (1983), pp. 474-477
[13.]
S.L. Ollerenshaw, A.J. Woolcock.
Characteristics of the inflammation in biopsies from large airways of subjects with asthma and subjects with chronic airflow limitation.
Am Rev Respir Dis, 145 (1992), pp. 922-927
[14.]
G.W. Hunninghake, R.G. Crystal.
Cigarette smoking and lung destruction. Accumulation of neutrophils in the lungs of cigarette smokers.
Am Rev Respir Dis, 128 (1983), pp. 833-838
[15.]
X.Y. Li, D. Brown, S. Smith, W. Macnee, K. Donaldson.
Short-term inflammatory responses following intratracheal instillation of fine and ultrafine carbon black in rats.
Inhal Toxicol, 11 (1999), pp. 709-731
[16.]
C. Monn, S. Becker.
Cytotoxicity and induction of proinflammatory cytokines from human monocytes exposed to fine (PM2.5) and coarse particles (PM10-2.5) in outdoor and indoor air.
Toxicol Appl Pharmacol, 155 (1999), pp. 245-252
[17.]
S. Salvi, A. Blomberg, B. Rudell, F. Kelly, T. Sandstrom, S.T. Holgate, et al.
Acute inflammatory responses in the airways and peripheral blood after short-term exposure to diesel exhaust in healthy human volunteers.
Am J Respir Crit Care Med, 159 (1999), pp. 702-709
[18.]
S.G. Von Essen, D.P. O’Neill, S. Mcgranaghan, S.A. Olenchock, S.I. Rennard.
Neutrophilic respiratory tract inflammation and peripheral blood neutrophilia after grain sorghum dust extract challenge.
Chest, 108 (1995), pp. 1425-1433
[19.]
S.G. Von Essen, R.A. Robbins, A.B. Thompson, R.F. Ertl, J. Linder, S.I. Rennard.
Mechanisms of neutrophil recruitment to the lung by grain dust exposure.
Am Rev Respir Dis, 138 (1988), pp. 921-927
[20.]
T.C. O’Shaughnessy, T.W. Ansari, N.C. Barnes, P.K. Jeffery.
Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1.
Am J Respir Crit Care Med, 155 (1997), pp. 852-857
[21.]
M. Saetta, A. Di Stefano, P. Maestrelli, A. Ferraresso, R. Drigo, A. Potena, et al.
Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis.
Am Rev Respir Dis, 147 (1993), pp. 301-306
[22.]
M. Saetta, A. Di Stefano, G. Turato, F.M. Facchini, L. Corbino, C.E. Mapp, et al.
CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 157 (1998), pp. 822-826
[23.]
J.G. Leopold, J. Goeff.
Centrilobular form of hypertrophic emphysema and its relation to chronic bronchitis.
Thorax, 12 (1957), pp. 219-235
[24.]
K.A. Mclean.
Pathogenesis of pulmonary emphysema.
Am J Med, 25 (1958), pp. 62-74
[25.]
J.E. Repine, A. Bast, I. Lankhorst.
Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group.
Am J Respir Crit Care Med, 156 (1997), pp. 341-357
[26.]
J.L. Wright, L. Lawson, P.D. Pare, R.O. Hooper, D.I. Peretz, J.M. Nelems, et al.
The structure and function of the pulmonary vasculature in mild chronic obstructive pulmonary disease. The effect of oxygen and exercise.
Am Rev Respir Dis, 128 (1983), pp. 702-707
[27.]
V.I. Peinado, J.A. Barbera, P. Abate, J. Ramirez, J. Roca, S. Santos, et al.
Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 159 (1999), pp. 1605-1611
[28.]
D.J. Riley, S. Thakker-Varia, G.J. Poiani, C.A. Tozzi.
Vascular remodeling.
The lung: scientific foundations, pp. 1589-1597
[29.]
W. Macnee.
Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part two.
Am J Respir Crit Care Med, 150 (1994), pp. 1158-1168
[30.]
N.B. Pride, P. Vermeire, L. Allegra.
Diagnostic labels applied to model case histories of chronic airflow obstruction. Responses to a questionnaire in 11 North American and Western European countries.
Eur Respir J, 2 (1989), pp. 702-709
[31.]
D.M. Mannino, C. Brown, G.A. Giovino.
Obstructive lung disease deaths in the United States from 1979 through 1993. An analysis using multiple-cause mortality data.
Am J Respir Crit Care Med, 156 (1997), pp. 814-818
[32.]
The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020,
[33.]
NATIONAL HEALTH SERVICE EXECUTIVE.
Burden of disease: a discussion document.
Department of Health, (1996),
[34.]
Molken M.P. Rutten-Van, M.J. Postma, M.A. Joore, M.L. Van Genugten, R. Leidl, J.C. Jager.
Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands.
Respir Med, 93 (1999), pp. 779-787
[35.]
L. Jacobson, P. Hertzman, C.-G. Lofdahl, B.-E. Skoogh, B. Lindgren.
The economic impact of asthma and COPD in Sweden 1980 and 1991.
Respir Med, 94 (2000), pp. 247-255
[36.]
A.S. Buist, W.M. Vollmer.
Smoking and other risk factors.
Textbook of respiratory medicine, pp. 1259-1287
[37.]
T.J. Thom.
International comparisons in COPD mortality.
Am Rev Respir Dis, 140 (1989), pp. S27-S34
[38.]
X. Xu, S.T. Weiss, B. Rijcken, J.P. Schouten.
Smoking, changes in smoking habits, and rate of decline in FEV1: new insight into gender differences.
Eur Respir J, 7 (1994), pp. 1056-1061
[39.]
M. Feinleib, H.M. Rosenberg, J.G. Collins, J.E. Delozier, R. Pokras, F.M. Chevarley.
Trends in COPD morbidity and mortality in the United States.
Am Rev Respir Dis, 140 (1989), pp. 9
[40.]
US CENTERS FOR DISEASE CONTROL AND PREVENTION.
Vital and health statistics: current estimates from the National Health Interview Survey, Department of Health and Human Services, Public Health Service, (1995),
[41.]
N.R. Anthonisen, J.E. Connett, J.P. Kiley, M.D. Altose, W.C. Bailey, A.S. Buist, et al.
Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1.
JAMA, 272 (1994), pp. 1497-1505
[42.]
C.B. Laurell, S. Eriksson.
The electrophoretic alpha-1 globulin pattern of serum in alpha-1 antitrypsin deficiency.
Scand J Clin Lab Invest, 15 (1963), pp. 132-140
[43.]
R.C. Hubbard, R.G. Crystal.
Antiproteases.
The lung: scientific foundations, pp. 1775-1787
[44.]
N.G. Mcelvaney, R.G. Crystal.
Inherited susceptibility of the lung to proteolytic injury.
The lung: scientific foundations, pp. 2537-2553
[45.]
H.J. Sluiter, N.G.M. Orie, K. De Vreis, K. Tammerling, J. Wikop.
The host factor in bronchitis.
Bronchitis, an international symposium, pp. 43-59
[46.]
B. Hagstrom, P. Nyberg, P.M. Nilsson.
Asthma in adult life – is there an association with birth weight?.
Scand J Prim Health Care, 16 (1998), pp. 117-120
[47.]
C. Svanes, E. Omenaas, J.M. Heuch, L.M. Irgens, A. Gulsvik.
Birth characteristics and asthma symptoms in young adults: results from a population-based cohort study in Norway.
Eur Respir J, 12 (1998), pp. 1366-1370
[48.]
T. Todisco, F.M. de Benedictis, L. Iannacci, S. Baglioni, A. Eslami, E. Todisco, et al.
Mild prematurity and respiratory functions.
Eur J Pediatr, 152 (1993), pp. 55-58
[49.]
C.E. Stein, K. Kumaran, C.H. Fall, S.O. Shaheen, C. Osmond, D.J. Barker.
Relation of fetal growth to adult lung function in South India.
Thorax, 52 (1997), pp. 895-899
[50.]
W.J. Morgan.
Maternal smoking and infant lung function. Further evidence for an in utero effect.
Am J Respir Crit Care Med, 158 (1998), pp. 689-690
[51.]
I.B. Tager, M.R. Segal, F.E. Speizer, S.T. Weiss.
The natural history of forced expiratory volumes. Effect of cigarette smoking and respiratory symptoms.
Am Rev Respir Dis, 138 (1988), pp. 837-849
[52.]
US SURGEON GENERAL.
The health consequences of smoking: chronic obstructive pulmonary disease, USDepartment of Health and Human Services, (1984),
[53.]
P. Leuenberger, J. Schwartz, U. Ackermann-Liebrich, K. Blaser, G. Bolognini, J.P. Bongard, et al.
Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA Study). Swiss Study on Air Pollution and Lung Diseases in Adults, SAPALDIA Team.
Am J Respir Crit Care Med, 150 (1994), pp. 1222-1228
[54.]
H.H. Dayal, S. Khuder, R. Sharrar, N. Trieff.
Passive smoking in obstructive respiratory disease in an industrialized urban population.
Environ Res, 65 (1994), pp. 161-171
[55.]
P.G. Holt.
Immune and inflammatory function in cigarette smokers.
Thorax, 42 (1987), pp. 241-249
[56.]
F. Kauffmann, D. Drouet, J. Lellouch, D. Brille.
Twelve years spirometric changes among Paris area workers.
Int J Epidemiol, 8 (1979), pp. 201-212
[57.]
D.E. Niewoehner.
Anatomic and pathophysiological correlations in COPD.
Textbook of pulmonary diseases, pp. 823-842
[58.]
J.C. Chen, M.D. Mannino.
Worldwide epidemiology of chronic obstructive pulmonary disease.
Current Opinion in Pulmonary Medicine, 5 (1999), pp. 93-99
[59.]
R. Perez-Padilla, U. Regalado, S. Vedal, P. Pare, R. Chapela, R. Sansores, et al.
Exposure to biomass smoke and chronic airway disease in Mexican women.
Am J Respir Crit Care Med, 154 (1996), pp. 701-706
[60.]
M. Dossing, J. Khan, F. Al-Rabiah.
Risk factors for chronic obstructive lung disease in Saudi Arabia.
Respiratory Med, 88 (1994), pp. 519-522
[61.]
D. Behera, S.K. Jindal.
Respiratory symptoms in Indian women using domestic cooking fuels.
Chest, 100 (1991), pp. 385-388
[62.]
K. Amoli.
Bronchopulmonary disease in Iranian housewives chronically exposed to indoor smoke.
Eur Respir J, 11 (1998), pp. 659-663
[63.]
R. Dennis, D. Maldonado, S. Norman, E. Baena, G. Martinez.
Woodsmoke exposure and risk for obstructive airways disease among women.
Chest, 109 (1996), pp. 115-119
[64.]
M.R. Pandey.
Prevalence of chronic bronchitis in a rural community of the Hill Region of Nepal.
Thorax, 39 (1984), pp. 331-336
[65.]
M.R. Pandey.
Domestic smoke pollution and chronic bronchitis in a rural community of the Hill Region of Nepal.
Thorax, 39 (1984), pp. 337-339
[66.]
J.M. Samet, M. Marbury, J. Spengler.
Health effects and sources of indoor air pollution.
Am Rev Respir Dis, 136 (1987), pp. 1486-1508
[67.]
X. Tao, C.J. Hong, S. Yu, B. Chen, H. Zhu, M. Yang.
Priority among air pollution factors for preventing chronic obstructive pulmonary disease in Shanghai.
Sci Total Environ, 127 (1992), pp. 57-67
[68.]
E. Prescott, P. Lange, J. Vestbo.
Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study.
Eur Respir J, 13 (1999), pp. 1109-1114
[69.]
D.P. Strachan.
Epidemiology: A British perspective.
Chronic obstructive pulmonary disease, pp. 47-67
[70.]
D. Georgopoulas, N.R. Anthonisen.
Symptoms and signs of COPD.
Chronic obstructive pulmonary disease, pp. 357-363
[71.]
B. Loveridge, P. West, M.H. Kryger, N.R. Anthonisen.
Alteration in breathing pattern with progression of chronic obstructive pulmonary disease.
Am Rev Respir Dis, 134 (1986), pp. 930-934
[72.]
S. Kesten, K.R. Chapman.
Physician perceptions and management of COPD.
Chest, 104 (1993), pp. 254-258
[73.]
A.L. Reis.
Response to bronchodilators.
Pulmonary function testing: guidelines and controversies,
[74.]
AMERICAN THORACIC SOCIETY.
Lung function testing: selection of reference values and interpretative strategies.
Am Rev Respir Dis, 144 (1991), pp. 1202-1218
[75.]
D.H. Wilson, M.A. Wakefield, I.D. Steven, R.A. Rohrsheim, A.J. Esterman, N.M. Graham.
“Sick of Smoking”: evaluation of a targeted minimal smoking cessation intervention in general practice.
Med J Aust, 152 (1990), pp. 518-521
[76.]
J. Britton, A. Knox.
Helping people to stop smoking: the new smoking cessation guidelines.
Thorax, 54 (1999), pp. 1-2
[77.]
M.C. Fiore, W.C. Bailey, S.J. Cohen.
Smoking cessation: information for specialists, US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research and Centers for Disease Control and Prevention, (1996),
[78.]
THE TOBACCO USE AND DEPENDENCE CLINICAL PRACTICE GUIDELINE PANEL, STAFF, AND CONSORTIUM REPRESENTATIVES.
A clinical practice guideline for treating tobacco use and dependence.
JAMA, 283 (2000), pp. 244-254
[79.]
AMERICAN MEDICAL ASSOCIATION.
Guidelines for the diagnosis and treatment of nicotine dependence: how to help patients stop smoking, American Medical Association, (1994),
[80.]
M.W. Manley, T.J. Glynn.
How to help your patients stop smoking.
A National Cancer Institute manual for physicians,
[81.]
T.J. Glynn, M.W. Manley, T.F. Pechacek.
Physician-initiated smoking cessation program: the National Cancer Institute trials.
Prog Clin Biol Res, 339 (1990), pp. 11-25
[82.]
M.C. Fiore, S.S. Smith, D.E. Jorenby, T.B. Baker.
The effectiveness of the nicotine patch for smoking cessation.
JAMA, 271 (1994), pp. 1940-1947
[83.]
T. Lancaster, L. Stead, C. Silagy, A. Sowden.
Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library.
BMJ, 321 (2000), pp. 355-358
[84.]
THE COPD GUIDELINES GROUP OF THE STANDARDS OF CARE COMMITTEE OF THE BTS.
BTS guidelines for the management of chronic obstructive pulmonary disease.
Thorax, 52 (1997), pp. S1-S28
[85.]
J. Samet, M.J. Utell.
Ambient air pollution.
Textbook of occupational and environmental medicine, pp. 53-60
[86.]
A.L. Ries, R.M. Kaplan, T.M. Limberg, L.M. Prewitt.
Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease.
Ann Intern Med, 122 (1995), pp. 823-832
[87.]
L.M. Janelli, Y.K. Scherer, L.E. Schmieder.
Can a pulmonary health teaching program alter patients’ ability to cope with COPD?.
Rehabil Nurs, 16 (1991), pp. 199-202
[88.]
T. Ashikaga, P.M. Vacek, S.O. Lewis.
Evaluation of a community-based education program for individuals with chronic obstructive pulmonary disease.
J Rehabil, 46 (1980), pp. 23-27
[89.]
M.T. Toshima, R.M. Kaplan, A.L. Ries.
Experimental evaluation of rehabilitation in chronic obstructive pulmonary disease: short-term effects on exercise endurance and health status.
Health Psychol, 9 (1990), pp. 237-252
[90.]
B.R. Celli.
Pulmonary rehabilitation in patients with COPD.
Am J Respir Crit Care Med, 152 (1995), pp. 861-864
[91.]
J.E. Heffner, B. Fahy, L. Hilling, C. Barbieri.
Outcomes of advance directive education of pulmonary rehabilitation patients.
Am J Respir Crit Care Med, 155 (1997), pp. 1055-1059
[92.]
M.A. Stewart.
Effective physician-patient communication and health outcomes: a review.
CMAJ, 152 (1995), pp. 1423-1433
[93.]
N.M. Clark, F. Nothwehr, M. Gong, D. Evans, L.A. Maiman, M.E. Hurwitz, et al.
Physician-patient partnership in managing chronic illness.
Acad Med, 70 (1995), pp. 957-959
[94.]
R.A. Pauwels, C.G. Lofdahl, L.A. Laitinen, J.P. Schouten, D.S. Postma, N.B. Pride, et al.
Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.
N Engl J Med, 340 (1999), pp. 1948-1953
[95.]
J. Vestbo, T. Sorensen, P. Lange, A. Brix, P. Torre, K. Viskum.
Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial.
Lancet, 353 (1999), pp. 1819-1823
[96.]
P.S. Burge, P.M. Calverley, P.W. Jones, S. Spencer, J.A. Anderson, T.K. Maslen.
Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.
BMJ, 320 (2000), pp. 1297-1303
[97.]
THE LUNG HEALTH STUDY RESEARCH GROUP.
Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease.
N Engl J Med, 343 (2000), pp. 1902-1909
[98.]
A.S. Vathenen, J.R. Britton, P. Ebden, J.B. Cookson, H.J. Wharrad, A.E. Tattersfield.
High-dose inhaled albuterol in severe chronic airflow limitation.
Am Rev Respir Dis, 138 (1988), pp. 850-855
[99.]
N.J. Gross, T.L. Petty, M. Friedman, M.S. Skorodin, G.W. Silvers, J.F. Donohue.
Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center study.
Am Rev Respir Dis, 139 (1989), pp. 1188-1191
[100.]
H. Chrystyn, B.A. Mulley, M.D. Peake.
Dose response relation to oral theophylline in severe chronic obstructive airways disease.
BMJ, 297 (1988), pp. 1506-1510
[101.]
B.G. Higgins, R.M. Powell, S. Cooper, A.E. Tattersfield.
Effect of salbutamol and iprapium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis.
Eur Respir J, 4 (1991), pp. 415-420
[102.]
S.C. Jenkins, R.W. Heaton, T.J. Fulton, J. Moxham.
Comparison of domiciliary nebulized salbutamol and salbutamol from a metered-dose inhaler in stable chronic airflow limitation.
Chest, 91 (1987), pp. 804-807
[103.]
A. Ikeda, K. Nishimura, H. Koyama, M. Tsukino, M. Mishima, T. Izumi.
Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease.
Thorax, 51 (1996), pp. 48-53
[104.]
G.H. Guyatt, M. Townsend, S.O. Pugsley, J.L. Keller, H.D. Short, D.W. Taylor, et al.
Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life.
Am Rev Respir Dis, 135 (1987), pp. 1069-1074
[105.]
P.W. Jones, T.K. Bosh.
Quality of life changes in COPD patients treated with salmeterol.
Am J Respir Crit Care Med, 155 (1997), pp. 1283-1289
[106.]
D.A. Mahler, J.F. Donohue, R.A. Barbee, M.D. Goldman, N.J. Gross, M.E. Wisniewski, et al.
Efficacy of salmeterol xinafoate in the treatment of COPD.
Chest, 115 (1999), pp. 957-965
[107.]
COMBIVENT INHALATION AEROSOL STUDY GROUP.
In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial.
Chest, 105 (1994), pp. 1411-1419
[108.]
COMBIVENT INHALATION SOLUTION STUDY GROUP.
Routine nebulized ipratropium and albuterol together are better than either alone in COPD.
Chest, 112 (1997), pp. 1514-1521
[109.]
N. Gross, D. Tashkin, R. Miller, J. Oren, W. Coleman, S. Linberg.
Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group.
Respiration, 65 (1998), pp. 354-362
[110.]
C.S. Ulrik.
Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study.
Thorax, 50 (1995), pp. 750-754
[111.]
D.R. Taylor, B. Buick, C. Kinney, R.C. Lowry, D.G. Mcdevitt.
The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction.
Am Rev Respir Dis, 131 (1985), pp. 747-751
[112.]
J.A. Van Noord, D.R. De Munck, T.A. Bantje, W.C. Hop, M.L. Akveld, A.M. Bommer.
Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium.
Eur Respir J, 15 (2000), pp. 878-885
[113.]
D. Murciano, M.H. Auclair, R. Pariente, M. Aubier.
A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease.
N Engl J Med, 320 (1989), pp. 1521-1525
[114.]
B.R. O’Driscoll, E.A. Kay, R.J. Taylor, H. Weatherby, M.C. Chetty, A. Bernstein.
A long-term prospective assessment of home nebulizer treatment.
Respir Med, 86 (1992), pp. 317-325
[115.]
D.P. Tashkin, E. Bleecker, S. Braun, S. Campbell, A.C. Degraff Jr., D.W. Hudgel, et al.
Results of a multicenter study of nebulized inhalant bronchodilator solutions.
Am J Med, 100 (1996), pp. S62-S99
[116.]
T. Senderovitz, J. Vestbo, J. Frandsen, N. Maltbaek, M. Norgaard, C. Nielsen, et al.
Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine.
Respir Med, 93 (1999), pp. 715-718
[117.]
K.L. Rice, J.B. Rubins, F. Lebahn, C.M. Parenti, P.G. Duane, M. Kuskowski, et al.
Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial.
Am J Respir Crit Care Med, 162 (2000), pp. 174-178
[118.]
M. Decramer, L.M. Lacquet, R. Fagard, P. Rogiers.
Corticosteroids contribute to muscle weakness in chronic airflow obstruction.
Am J Respir Crit Care Med, 150 (1994), pp. 11-16
[119.]
M. Decramer, K.J. Stas.
Corticosteroid-induced myopathy involving respiratory muscles in patients with chronic obstructive pulmonary disease or asthma.
Am Rev Respir Dis, 146 (1992), pp. 800-802
[120.]
K.L. Nichol, K.L. Margolis, J. Wuorenma, T. Von Sternberg.
The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community.
N Engl J Med, 331 (1994), pp. 778-784
[121.]
K.M. Edwards, W.D. Dupont, M.K. Westrich, W.D. Plummer Jr., P.S. Palmer, P.F. Wright.
A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease.
J Infect Dis, 169 (1994), pp. 68-76
[122.]
M.S. Simberkoff, A.P. Cross, M. Al-Ibrahim, A.L. Baltch, P.J. Geiseler, J. Nadler, et al.
Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study.
N Engl J Med, 315 (1986), pp. 1318-1327
[123.]
J.H. Williams Jr., K.M. Moser.
Pneumococcal vaccine and patients with chronic lung disease.
Ann Intern Med, 104 (1986), pp. 106-109
[124.]
A.L. Davis, C.P. Aranda, G. Schiffman, L.C. Christianson.
Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study.
Chest, 92 (1987), pp. 204-212
[125.]
C.M. Isada, J.K. Stoller.
Chronic bronchitis: the role of antibiotics.
Respiratory infections: a scientific basis for management, pp. 621-633
[126.]
AMERICAN THORACIC SOCIETY.
Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 152 (1995), pp. S77-S121
[127.]
N.M. Siafakas, P. Vermeire, N.B. Pride, P. Paoletti, J. Gibson, P. Howard, et al.
Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force.
Eur Respir J, 8 (1995), pp. 1398-1420
[128.]
P.J. Poole, P.N. Black.
Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, (2000), pp. 2
[129.]
N.C. Hansen, A. Skriver, L. Brorsen-Riis, S. Balslov, T. Evald, N. Maltbaek, et al.
Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis.
Respir Med, 88 (1994), pp. 531-535
[130.]
BRITISH THORACIC SOCIETY RESEARCH COMMITTEE.
Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction.
Thorax, 40 (1985), pp. 832-835
[131.]
G. Boman, U. Backer, S. Larsson, B. Melander, L. Wahlander.
Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases.
Eur J Respir Dis, 64 (1983), pp. 405-415
[132.]
J.B. Rasmussen, C. Glennow.
Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis.
Eur Respir J, 1 (1988), pp. 351-355
[133.]
J.P. Collet, P. Shapiro, P. Ernst, T. Renzi, T. Ducruet, A. Robinson.
Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant.
Am J Respir Crit Care Med, 156 (1997), pp. 1719-1724
[134.]
N.R. Anthonisen.
OM-8BV for COPD.
Am J Respir Crit Care Med, 156 (1997), pp. 1713-1714
[135.]
R.S. Irwin, L.P. Boulet, M.M. Cloutier, R. Fuller, P.M. Gold, V. Hoffstein, et al.
Managing cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians.
Chest, 114 (1998), pp. S133-S181
[136.]
J.A. Barbera, N. Roger, J. Roca, I. Rovira, T.W. Higenbottam, R. Rodriguez-Roisin.
Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease.
Lancet, 347 (1996), pp. 436-440
[137.]
A.T. Jones, T.W. Evans.
NO: COPD and beyond.
Thorax, 52 (1997), pp. S16-S21
[138.]
P.A. Bardsley, P. Howard, W. Debacker, P. Vermeire, M. Mairesse, C. Ledent, et al.
Two years treatment with almitrine bismesylate in patients with hypoxic chronic obstructive airways disease.
Eur Respir J, 4 (1991), pp. 308-310
[139.]
S. Watanabe, R.E. Kanner, A.G. Cutillo, R.L. Menlove, R.T. Bachand Jr., M.B. Szalkowski, et al.
Long-term effect of almitrine bismesylate in patients with hypoxemic chronic obstructive pulmonary disease.
Am Rev Respir Dis, 140 (1989), pp. 1269-1273
[140.]
B.R. Winkelmann, T.H. Kullmer, D.G. Kneissl, D. Trenk, H. Kronenberger.
Low-dose almitrine bismesylate in the treatment of hypoxemia due to chronic obstructive pulmonary disease.
Chest, 105 (1994), pp. 1383-1391
[141.]
N. Eiser, W.T. Denman, C. West, P. Luce.
Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the “pink puffer” syndrome.
Eur Respir J, 4 (1991), pp. 926-931
[142.]
I.H. Young, E. Daviskas, V.A. Keena.
Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease.
Thorax, 44 (1989), pp. 387-390
[143.]
K.L. Rice, R.S. Kronenberg, L.L. Hedemark, D.E. Niewoehner.
Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction.
Br J Dis Chest, 81 (1987), pp. 287-292
[144.]
A.A. Woodcock, E.R. Gross, A. Gellert, S. Shah, M. Johnson, D.M. Geddes.
Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases.
N Engl J Med, 305 (1981), pp. 1611-1616
[145.]
P.J. Poole, A.G. Veale, P.N. Black.
The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 157 (1998), pp. 1877-1880
[146.]
M.J. Berry, W.J. Rejeski, N.E. Adair, D. Zaccaro.
Exercise rehabilitation and chronic obstructive pulmonary disease stage.
Am J Respir Crit Care Med, 160 (1999), pp. 1248-1253
[147.]
K. Foglio, L. Bianchi, G. Bruletti, L. Battista, M. Pagani, N. Ambrosino.
Long-term effectiveness of pulmonary rehabilitation in patients with chronic airway obstruction.
Eur Respir J, 13 (1999), pp. 125-132
[148.]
P. Young, M. Dewse, W. Fergusson, J. Kolbe.
Improvements in outcomes for chronic obstructive pulmonary disease (COPD) attributable to a hospital-based respiratory rehabilitation programme.
Aust N Z J Med, 29 (1999), pp. 59-65
[149.]
T.L. Griffiths, M.L. Burr, I.A. Campbell, V. Lewis-Jenkins, J. Mullins, K. Shiels, et al.
Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial.
Lancet, 355 (2000), pp. 362-368
[150.]
R.S. Goldstein, E.H. Gort, D. Stubbing, M.A. Avendano, G.H. Guyatt.
Randomised controlled trial of respiratory rehabilitation.
Lancet, 344 (1994), pp. 1394-1397
[151.]
P.J. Wijkstra, R. Van Altena, J. Kraan, V. Otten, D.S. Postma, G.H. Koeter.
Quality of life in patients with chronic obstructive pulmonary disease improves after rehabilitation at home.
Eur Respir J, 7 (1994), pp. 269-723
[152.]
C.R. Mcgavin, S.P. Gupta, E.L. Lloyd, G.J. Mchardy.
Physical rehabilitation for the chronic bronchitic: results of a controlled trial of exercises in the home.
Thorax, 32 (1977), pp. 307-311
[153.]
NOCTURNAL OXYGEN THERAPY TRIAL GROUP.
Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial.
Ann Intern Med, 93 (1980), pp. 391-398
[154.]
REPORT OF THE MEDICAL RESEARCH COUNCIL WORKING PARTY.
Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema.
[155.]
S.P. Tarpy, B.R. Celli.
Long-term oxygen therapy.
N Engl J Med, 333 (1995), pp. 710-714
[156.]
R.J. Mehran, J. Deslauriers.
Indications for surgery and patient work-up for bullectomy.
Chest Surg Clin N Am, 5 (1995), pp. 717-734
[157.]
J.O. Benditt, R.K. Albert.
Surgical options for patients with advanced emphysema.
Clin Chest Med, 18 (1997), pp. 577-593
[158.]
D. Geddes, M. Davies, H. Koyama, D. Hansell, U. Pastorino, J. Pepper, et al.
Effect of lung-volume-reduction surgery in patients with severe emphysema.
N Engl J Med, 343 (2000), pp. 239-245
[159.]
THE NATIONAL EMPHYSEMA TREATMENT TRIAL RESEARCH GROUP.
Rationale and design of The National Emphysema Treatment Trial: a prospective randomized trial of lung volume reduction surgery.
Chest, 116 (1999), pp. 1750-1761
[160.]
E.P. Trulock.
Lung transplantation.
Am J Respir Crit Care Med, 155 (1997), pp. 789-818
[161.]
J. Theodore, N. Lewiston.
Lung transplantation comes of age.
N Engl J Med, 322 (1990), pp. 772-774
[162.]
J.D. Hosenpud, L.E. Bennett, B.M. Keck, B. Fiol, M.M. Boucek, R.J. Novick.
The Registry of the International Society for Heart and Lung Transplantation: fifteenth official report – 1998.
J Heart Lung Transplant, 17 (1998), pp. 656-668
[163.]
ANNUAL REPORT OF THE US SCIENTIFIC REGISTRY FOR TRANSPLANT RECIPIENTS AND THE ORGAN PROCUREMENT AND TRANSPLANTATION NETWORK.
Transplant data: 1988-1994, Division of Transplantation, Health Resources and Services Administration, US Department of Health and Human Services, (1995),
[164.]
J.R. Maurer, A.E. Frost, M. Estenne, T. Higenbottam, A.R. Glanville.
International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society.
Transplantation, 66 (1998), pp. 951-956
[165.]
C.R. Regueiro, M.B. Hamel, R.B. Davis, N. Desbiens, A.F. Connors Jr., R.S. Phillips.
A comparison of generalist and pulmonologist care for patients hospitalized with severe chronic obstructive pulmonary disease: resource intensity, hospital costs, and survival. SUPPORT Investigators.
Am J Med, 105 (1998), pp. 366-372
[166.]
P.G. Gibson, J.H. Wlodarczyk, A.J. Wilson, A. Sprogis.
Severe exacerbation of chronic obstructive airways disease: health resource use in general practice and hospital.
J Qual Clin Pract, 18 (1998), pp. 125-133
[167.]
P.M. Warren, D.C. Flenley, J.S. Millar, A. Avery.
Respiratory failure revisited: acute exacerbations of chronic bronchitis between 1961-68 and 1970-76.
Lancet, 1 (1980), pp. 467-470
[168.]
N.R. Anthonisen, J. Manfreda, C.P. Warren, E.S. Hershfield, G.K. Harding, N.A. Nelson.
Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.
Ann Intern Med, 106 (1987), pp. 196-204
[169.]
R. Wilson.
The role of infection in COPD.
Chest, 113 (1998), pp. S242-S248
[170.]
N. Soler, A. Torres, S. Ewig, J. Gonzalez, R. Celis, M. El-Ebiary, et al.
Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation.
Am J Respir Crit Care Med, 157 (1998), pp. 1498-1505
[171.]
C.B. Smith, R.E. Kanner, C.A. Golden, M.R. Klauber, A.D. Renzetti Jr..
Effect of viral infections on pulmonary function in patients with chronic obstructive pulmonary diseases.
J Infect Dis, 141 (1980), pp. 271-280
[172.]
J.T. Macfarlane, A. Colville, A. Guion, R.M. Macfarlane, D.H. Rose.
Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community.
Lancet, 341 (1993), pp. 511-514
[173.]
R.A. Stockley, C. O’Brien, A. Pye, S.L. Hill.
Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD.
Chest, 117 (2000), pp. 1638-1645
[174.]
H.R. Anderson, C. Spix, S. Medina, J.P. Schouten, J. Castellsague, G. Rossi, et al.
Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project.
Eur Respir J, 10 (1997), pp. 1064-1071
[175.]
S. Chodosh, J. McCarty, S. Farkas, M. Drehobl, R. Tosiello, M. Shan, et al.
Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.
Clin Infect Dis, 27 (1998), pp. 722-729
[176.]
E.E. Walsh, A.R. Falsey, P.A. Hennessey.
Respiratory syncytial and other virus infections in persons with chronic cardiopulmonary disease.
Am J Respir Crit Care Med, 160 (1999), pp. 791-795
[177.]
N. Mogulkoc, S. Karakurt, B. Isalska, U. Bayindir, T. Celikel, V. Korten, et al.
Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection.
Am J Respir Crit Care Med, 160 (1999), pp. 349-353
[178.]
T.F. Murphy, S. Sethi, K.L. Klingman, A.B. Brueggemann, G.V. Doern.
Simultaneous respiratory tract colonization by multiple strains of nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease: implications for antibiotic therapy.
J Infect Dis, 180 (1999), pp. 404-409
[179.]
C.L. Emerman, D. Effron, T.W. Lukens.
Spirometric criteria for hospital admission of patients with acute exacerbation of COPD.
Chest, 99 (1991), pp. 595-599
[180.]
C.L. Emerman, T.W. Lukens, D. Effron.
Physician estimation of FEV1 in acute exacerbation of COPD.
Chest, 105 (1994), pp. 1709-1712
[181.]
C.L. Emerman, R.K. Cydulka.
Use of peak expiratory flow rate in emergency department evaluation of acute exacerbation of chronic obstructive pulmonary disease.
Ann Emerg Med, 27 (1996), pp. 159-163
[182.]
C.L. Emerman, A.F. Connors, T.W. Lukens, D. Effron, M.E. May.
Relationship between arterial blood gases and spirometry in acute exacerbations of chronic obstructive pulmonary disease.
Ann Emerg Med, 18 (1989), pp. 523-527
[183.]
W.H. Thompson, C.P. Nielson, P. Carvalho, N.B. Charan, J.J. Crowley.
Controlled trial of oral prednisone in outpatients with acute COPD exacerbation.
Am J Respir Crit Care Med, 154 (1996), pp. 407-412
[184.]
L. Davies, R.M. Angus, P.M. Calverley.
Oral cortico-steroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial.
Lancet, 354 (1999), pp. 456-460
[185.]
D.E. Niewoehner, M.L. Erbland, R.H. Deupree, D. Collins, N.J. Gross, R.W. Light, et al.
Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group.
N Engl J Med, 340 (1999), pp. 1941-1947
[186.]
A.F. Connors Jr., N.V. Dawson, C. Thomas, F.E. Harrell Jr., N. Desbiens, W.J. Fulkerson, et al.
Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators.
Am J Respir Crit Care Med, 154 (1996), pp. 959-967
[187.]
S. Shepperd, D. Harwood, A. Gray, M. Vessey, P. Morgan.
Randomised controlled trial comparing hospital at home care with inpatient hospital care. II: cost minimisation analysis.
BMJ, 316 (1998), pp. 1791-1796
[188.]
J.H. Gravil, O.A. Al-Rawas, M.M. Cotton, U. Flani, A. Ganirwin, R.D. Stevenson.
Home treatment of exacerbations of chronic obstructive pulmonary disease by an acute respiratory assessment service.
Lancet, 351 (1998), pp. 1853-1855
[189.]
P. Moayyedi, J. Congleton, R.L. Page, S.B. Pearson, M.F. Muers.
Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease.
Thorax, 50 (1995), pp. 834-837
[190.]
A. Fernandez, J. Munoz, B. De La Calle, I. Alia, A. Ezpeleta, M.A. De La Cal, et al.
Comparison of one versus two bronchodilators in ventilated COPD patients.
Intensive Care Med, 20 (1994), pp. 199-202
[191.]
J.A. Barbera, A. Reyes, J. Roca, J.M. Montserrat, P.D. Wagner, R. Rodriguez-Roisin.
Effect of intravenously administered aminophylline on ventilation/perfusion inequality during recovery from exacerbations of chronic obstructive pulmonary disease.
Am Rev Respir Dis, 145 (1992), pp. 1328-1333
[192.]
J.L. Mahon, A. Laupacis, R.V. Hodder, D.A. Mckim, N.A. Paterson, T.E. Wood, et al.
Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice.
Chest, 115 (1999), pp. 38-48
[193.]
P. Lloberes, L. Ramis, J.M. Montserrat, J. Serra, J. Campistol, C. Picado, et al.
Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease.
Eur Respir J, 1 (1988), pp. 536-539
[194.]
D. Murciano, M. Aubier, Y. Lecocguic, R. Pariente.
Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease.
N Engl J Med, 311 (1984), pp. 349-353
[195.]
C.L. Emerman, A.F. Connors, T.W. Lukens, M.E. May, D. Effron.
Theophylline concentrations in patients with acute exacerbation of COPD.
Am J Emerg Med, 8 (1990), pp. 289-292
[196.]
T.J. Meyer, N.S. Hill.
Noninvasive positive pressure ventilation to treat respiratory failure.
Ann Intern Med, 120 (1994), pp. 760-770
[197.]
INTERNATIONAL CONSENSUS CONFERENCES IN INTENSIVE CARE.
MEDICINE: noninvasive positive pressure ventilation in acute respiratory failure.
Am J Respir Crit Care Med, 163 (2001), pp. 283-291
[198.]
J. Bott, M.P. Carroll, J.H. Conway, S.E. Keilty, E.M. Ward, A.M. Brown, et al.
Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease.
Lancet, 341 (1993), pp. 1555-1557
[199.]
L. Brochard, J. Mancebo, M. Wysocki, F. Lofaso, G. Conti, A. Rauss, et al.
Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease.
N Engl J Med, 333 (1995), pp. 817-822
[200.]
N. Kramer, T.J. Meyer, J. Meharg, R.D. Cece, N.S. Hill.
Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure.
Am J Respir Crit Care Med, 151 (1995), pp. 1799-1806
[201.]
P.K. Plant, J.L. Owen, M.W. Elliott.
Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial.
Lancet, 355 (2000), pp. 1931-1935
[202.]
A. Esteban, A. Anzueto, I. Alia, F. Gordo, C. Apezteguia, F. Palizas, et al.
How is mechanical ventilation employed in the intensive care unit? An international utilization review.
Am J Respir Crit Care Med, 161 (2000), pp. 1450-1458
[203.]
A. Esteban, F. Frutos, M.J. Tobin, I. Alia, J.R. Solsona, I. Valverdu, et al.
for the Spanish Lung Failure Collaborative Group. A comparison of four methods of weaning patients from mechanical ventilation.
N Engl J Med, 332 (1995), pp. 345-350
[204.]
L. Brochard, A. Rauss, S. Benito, G. Conti, J. Mancebo, N. Rekik, et al.
Comparison of three methods of gradual withdrawal from ventilatory support during weaning from mechanical ventilation.
Am J Respir Crit Care Med, 150 (1994), pp. 896-903
[205.]
S. Nava, N. Ambrosino, E. Clini, M. Prato, G. Orlando, M. Vitacca, et al.
Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease. A randomized, controlled trial.
Ann Intern Med, 128 (1998), pp. 721-728
[206.]
G. Hilbert, D. Gruson, L. Portel, G. Gbikpi-Benissan, J.P. Cardinaud.
Noninvasive pressure support ventilation in COPD patients with postextubation hypercapnic respiratory insufficiency.
Eur Respir J, 11 (1998), pp. 1349-1353
[207.]
R. Kessler, M. Faller, G. Fourgaut, B. Mennecier, E. Weitzenblum.
Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 159 (1999), pp. 158-164
[208.]
A.I. Mushlin, E.R. Black, C.A. Connolly, K.M. Buonaccorso, S.W. Eberly.
The necessary length of hospital stay for chronic pulmonary disease.
JAMA, 266 (1991), pp. 80-83
[209.]
J.K. Stoller, P.A. Lange.
Inpatient management of chronic obstructive pulmonary disease.
Respir Care Clin N Am, 4 (1998), pp. 425-438
[211.]
H. Peach, M.S. Pathy.
Follow-up study of disability among elderly patients discharged from hospital with exacerbations of chronic bronchitis.
Thorax, 36 (1981), pp. 585-589
Copyright © 2001. Sociedade Portuguesa de Pneumologia/SPP
Pulmonology

Subscribe to our newsletter

Article options
Tools

Are you a health professional able to prescribe or dispense drugs?